子宫内膜癌中ER与PR表达与生存的关系
本研究采用重复肿瘤组织微阵列(TMA)数字图像,由两名病理学家独立半定量评估子宫内膜癌ER与PR表达的强度和比例,意见不一致者复核后达成最终评分。多因素分析显示ER比例评分(P=0.05)、ER强度评分(P=0.003)和PR综合评分(P=0.04)降低与肿瘤相关死亡率升高相关;ER/PR联合表达降低者的EC特异性生存差于任一受体单独降低者(P=0.005),但激素受体状态未显著改善个体水平的死亡预测。
要点
- ER比例评分(P=0.05)、ER强度评分(P=0.003)、PR综合评分(P=0.04)降低与肿瘤相关死亡率升高相关
- ER/PR联合表达降低者的EC特异性生存差于任一受体单独降低者(P=0.005)
- 激素受体状态未显著改善个体病例的死亡预测
核心结论
- 调整已知预后因素后,采用可捕捉评分与芯间变异的截点,ER与PR联合表达与子宫内膜癌特异性生存显著相关。
- 在个体水平,ER与PR表达并未改善死亡预测。
研究设计与样本
- 由两名病理学家利用重复肿瘤组织微阵列(TMA)数字图像,独立半定量评估子宫内膜癌肿瘤细胞ER与PR表达的强度和比例。
- 初次评估不一致的病例经复核后达成最终评分。
- 采用Cox回归分析评估总生存和EC特异性生存与激素受体表达(强度、比例及综合)的关联,并用C指数评价加入ER与PR状态后模型的区分度。
主要发现
- 255例患者的659份TMA可行ER分析,243例患者的459份TMA可行PR分析。
- 初次ER和PR评分一致的病例分别占82%和80%。
- 多因素分析中ER与PR表达降低与肿瘤相关死亡率升高相关。
- ER比例评分(P=0.05)、ER强度评分(P=0.003)、PR综合评分(P=0.04)的关联达到统计学显著。
- ER/PR联合表达降低者的EC特异性生存差于任一激素受体单独表达降低者(P=0.005)。
局限性
- 激素受体状态在个体病例中未显著改善死亡预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To measure association between endometrial carcinoma ER and PR status and endometrial cancer (EC) survival, accounting for inter-observer variation. METHODS: The intensity and proportion of tumor cell expression of ER and PR in ECs were assessed independently and semi-quantitatively by two pathologists using digital images of duplicate tumor tissue microarrays (TMAs). Cases with inconsistent initial assessment were reviewed and final scoring agreed. The association between overall and EC-specific survival and hormone receptor expression (intensity, proportion and combined) was assessed using Cox regression analysis. The C-index was used to evaluate model discrimination with addition of ER and PR status. RESULTS: Tumor ER and PR analysis was possible in 659 TMAs from 255 patients, and in 459 TMAs from 243 patients, respectively. Initial ER and PR scoring was consistent in 82% and 80% of cases, respectively. In multivariate analyses decreased ER and PR expression was associated with increased tumor-related mortality. Associations reached statistical significance for ER proportion score (P=0.05), ER intensity score (P=0.003), and PR combined score (P=0.04). Decreased expression of combined ER/PR expression was associated with poorer EC-specific survival than decreased expression of either hormone receptor alone (P=0.005). However, hormone receptor status did not significantly improve mortality prediction in individual cases. CONCLUSION: ER and PR expression combined, using cut-points that capture variation in scoring and across cores, is significantly associated with EC-specific survival in analyses adjusting for known prognostic factors. However, at the individual level, ER and PR expression does not improve mortality prediction.
引用
- Smith D, Stewart CJR, Clarke EM, et al. ER and PR expression and survival after endometrial cancer. Gynecol Oncol. 2017. PMID: 29217139. doi:10.1016/j.ygyno.2017.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。